Gabitril tablets out of stock until end of October - update
UPDATE: Following our earlier news story, we have been informed by Teva UK that all strengths of Gabitril will be out of stock in the UK until the end of October, with possible additional shortages of Gabitril 10mg strength in early 2020.
Teva UK has sent us the following statement:
"Further to our communication dated 02 August 2019 we’re very sorry to say that the expected return to market date of Gabitril (tiagabine) has been extended to the end of October. Due to factors outside our control, part of the manufacturing process to make Gabitril has had problems that are affecting supply. This is a Europe wide issue, and we expect UK batches of all strengths to be released to pharmacies at the end of October. This will help for a while, but we’ve learned that the same manufacturing problems may mean that Gabitril 10mg may experience further disruption in supply in early 2020.
We’re very sorry about this. Our goal is to provide the medicines that patients need and we’re not happy with this situation, but we’d like to reassure all patients that we are working hard to resolve it as soon as we can. We have been in regular contact with the Department of Health and Social Care, who are aware of the situation and we will continue to update them.
For patients who are due to run out of Gabitril tablets before the end of October, we recommend that they contact the healthcare professional who prescribes their medicine for advice. For any other queries please contact our customer service team on 0800 590502. Please note we can’t offer advice in the context of a patient specific medical need and future treatment plan; for this we advise patients to consult their prescriber."
Please note that there are limited supplies remaining of Gabitril 10mg tablets at some depots. If pharmacies are having difficulty obtaining this stock, Teva Customer Services will be happy to take calls from pharmacies and will work to redistribute this stock around the UK. Their number is 0800 590 502.
DHSC has advised that clinicians could also consider prescribing unlicensed imports from abroad, working with relevant guidance and NHS Trust or local governance procedures.
Tiagabine in classed as a category 3 anti-epileptic drug (AED) by the MHRA. This means that individuals can be switched between different versions of their epilepsy medications and that these medications can be prescribed generically.
For people who do not have enough supplies of their medication, we recommend they see their GP as soon as possible to discuss further medication management.